Several genetically engineered mouse model (GEMMs) for RCC have also been developed [25] such as the MYC oncogene activation, Vhl-del, cyclin Cdkn2a-del, Ink4a/Arf-del model [26], the BRCA1 associated protein-1 (Bap1) and Polybromo 1 (Pbrm1) inactivation model [27]. The gene discussed is MYC; the disease is renal cell adenocarcinoma.